Search Results 1831-1840 of 17037 for magnesiummagnesium

1. Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer - Mayo Clinic

   Creatinine =< 1.5 mg/dL OR calculated creatinine clearance of >= 50 ml/min by either the Cockcroft-Gault formula or 24-hours urine collection analysis ...

2. Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH - Mayo Clinic

   Is pregnant/has a positive serum or urine pregnancy test. 11. Has received more than 12 doses (or 720 mg) of oral nimodipine (as a solution [e.g., Nymalize] ...

3. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer - Mayo Clinic

   ... mg prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible. Exception: participants with asymptomatic, untreated brain ...

4. Proton Pump Inhibitors Archives - Mayo Clinic News Network

   Less stomach acid also can make it harder for your body to absorb nutrients, such as magnesium, iron, vitamin B-12 and calcium. Evidence suggests an ...

5. A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML - Mayo Clinic

   corticosteroids (≤20 mg/day of prednisone or equivalent), topical, or inhaled corticosteroids 2. During study therapy, subjects may use systemic, topical ...

6. MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer - Mayo Clinic

   Lifetime exposure to doxorubicin ≤240 mg/m2 (or equivalent biologic dose if prior exposure to a different anthracycline). Candidate for surgical placement ...

7. A Study of Poziotinib in Patients with NSCLC With EGFR or HER2 Exon 20 Insertion Mutation - Mayo Clinic

   Total bilirubin ≤ 2 mg/dL; if hepatic metastases are present, ≤ 2.5 × ULN;; SGOT (AST) and SGPT (ALT) ≤ 2.5×ULN with the following exception; Patients ...

8. Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) - Mayo Clinic

   ... mg/m\^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA) exposure is allowed, as long as not for AML diagnosis * Participants must not have ...

9. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

   Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's syndrome;; Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion (except ...

10. A Study to Evaluate Docetaxel With or Without Bintrafusp Alfa to Treat Patients with Advanced Non-small Cell Lung Cancer - Mayo Clinic

    Taking oral prednisone of ≥ 10 mg daily or equivalent. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis ...